Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
Simcere Announces Strategic Partnership with Reyoung Bio to Secure Exclusive Commercialization Rights for Long-Acting RSV Monoclonal Antibody
Cosela® Receives Approval for a New Indication, Expanding Full-Cycle, Multi-Lineage Myeloprotection Across All Chemotherapy Lines for Extensive-Stage Small Cell Lung Cancer
Simcere and Schrödinger Enter Global Drug Discovery and Development Collaboration
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
Simcere Zaiming Announces First Patient Enrolled in Phase I Clinical Trial of Anti-LRRC15 ADC SIM0613
Simcere Zaiming Presents 9 Studies at the 2026 ASCO Annual Meeting
Simcere Zaiming’s Pan-RAS Inhibitor SIM0532 Doses First Patient in Clinical Trial
Simcere Zaiming’s LRRC15-Targeting ADC SIM0613 Receives IND Approval in China
FDA Granted Fast Track Designation for SIM0505 (CDH6 ADC) for the Treatment of Ovarian Cancer